ArticleScientific data2026
Comprehensive Transcriptome Profiling of Sporadic Medullary Thyroid Carcinomas.
Article in Scientific data, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Medullary thyroid carcinoma (MTC) is a rare thyroid cancer arising from parafollicular C cells belonging to the heterogeneous class of neuroendocrine neoplasms. Mutations in the RET and RAS genes are detected in approximately 50% to 80% of sporadic MTCs, while other genetic alterations are relatively uncommon. Only a few transcriptomic studies of this neoplasia have been performed, and the biology and the molecular mechanisms underlying its progression remain largely unknown. In this study, we performed transcriptome profiling of a cohort comprising 72 MTC specimens from patients with different genetic backgrounds. The presented data highlighted the molecular heterogeneity of MTCs and the need for personalized treatment strategies. For this reason, the obtained profiles could offer novel perspectives into the molecular landscape of this neoplasm within the scientific community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.